Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksThrogmorton Trust Regulatory News (THRG)

Share Price Information for Throgmorton Trust (THRG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 604.00
Bid: 606.00
Ask: 608.00
Change: -2.00 (-0.33%)
Spread: 2.00 (0.33%)
Open: 610.00
High: 610.00
Low: 604.00
Prev. Close: 606.00
THRG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Portfolio Update

29 Nov 2018 10:52

BlackRock Throgmorton Trust Plc - Portfolio Update

BlackRock Throgmorton Trust Plc - Portfolio Update

PR Newswire

London, November 29

BLACKROCK THROGMORTON TRUST PLC (LEI: 5493003B7ETS1JEDPF59) 

All information is at 31 October 2018 and unaudited.Performance at month end is calculated on a cum income basis

One Month %Three months %One year %Three years %Five years %
Net asset value-11.7-13.8-2.644.378.1
Share price-13.3-14.25.057.480.6
Benchmark*-8.3-9.4-8.819.534.4

Sources: BlackRock and Datastream

*With effect from 22 March 2018 the Numis Smaller Companies plus AIM (excluding Investment Companies) Index replaced the Numis Smaller Companies excluding AIM (excluding Investment Companies) Index as the Company’s benchmark. The five year period indices have been blended to reflect this.

At month end
Net asset value capital only:521.49p
Net asset value incl. income:529.43p
Share price475.00p
Discount to cum income NAV10.3%
Net yield1:2.0%
Total Gross assets2:£387.2m
Net market exposure as a % of net asset value3:103.0%
Ordinary shares in issue4:73,130,326
2017 ongoing charges* (excluding performance fees)5,6:0.9%
2017 ongoing charges* ratio (including performance fees)5,6,7:2.2%

*Ongoing Charges: The management fee rate reductions, as detailed in the notes below impact management fees in 2017 and onwards. The impact of the new fee arrangements, assuming the same level of performance from the manager and assuming all other charges remain the same, would be to reduce the level of Ongoing Charges borne by the Company.1. Calculated using the 2018 interim dividend declared on 26 July 2018 and paid on 29 August 2018, together with the 2017 final dividend declared on 12 February 2018 and paid on 29 March 2018.

2. Includes current year revenue and excludes gross exposure through contracts for difference.

3. Long positions less short positions as a percentage of net asset value.

4. Excluding 7,400,000 shares held in treasury.

5. Calculated as a percentage of average net assets and using expenses, excluding performance fees and interest costs for the year ended 30 November 2017.

6. With effect from 1 August 2017 the base management fee was reduced from 0.70% to 0.35% of gross assets per annum.

7. Effective 1st December 2017 the annual performance fee is calculated using performance data on an annualised rolling two year basis (previously, one year) and the maximum annual performance fee payable is effectively reduced to 0.90% of two year rolling average month end gross assets (from 1% of average annual gross assets over one year). Additionally, the Company now accrues this fee at a rate of 15% of outperformance (previously 10%). The maximum annual total fees (comprising the base management fee of 0.35% and a potential performance fee of 0.90%) are therefore 1.25% of average month end gross assets on a two year rolling basis (from 1.70% of average annual gross assets).

 

Sector Weightings% of Total Assets
Industrials26.1
Financials21.4
Consumer Services17.0
Technology11.8
Health Care7.1
Consumer Goods6.2
Basic Materials3.0
Oil & Gas1.1
Net current assets6.3
-----
Total100.0
=====

Market Exposure (Quarterly)
30.11.17 %28.02.18 %31.05.18 %31.08.18 %
Long116.9119.6115.9119.4
Short6.38.410.09.6
Gross exposure123.2128.0125.9129.0
Net exposure110.6111.2105.9109.8

Ten Largest Investments
Company% of Total Gross Assets
Ascential3.3
Hiscox2.8
Dechra Pharmaceuticals2.8
SSP2.8
Craneware2.7
Bodycote2.6
Workspace Group2.4
Aveva2.3
4imprint Group2.3
Robert Walters2.1

Commenting on the markets, Dan Whitestone, representing the Investment Manager noted:

During October the Company’s NAV per share fell 11.7%1 to 521.49p on a cum income basis, underperforming our benchmark, the Numis Smaller Companies plus AIM (excluding Investment Companies) Index, which fell by 8.3%1; the large cap FTSE 100 Index fell by 4.9%1 (all performance figures are in sterling terms with income reinvested).

October proved to be another challenging month for the Company. Equity markets globally experienced a sharp sell-off during month, with the UK market recording its worst monthly return in over three years. While the short book contributed a positive return of 70 basis points, this was unfortunately not enough to offset the underperformance of the long book. There was also a notable rotation away from highly rated shares (i.e. those that look expensive at face value), and higher momentum shares (i.e. those that have performed well), resulting in growth shares underperforming value. This dynamic acted as a significant headwind to performance given our growth orientated style. As the sell-off was most pronounced in growth assets like tech companies, or small and mid-caps, several of our longs fell more heavily than the benchmark without any specific negative newsflow, e.g. Fever-Tree, Integrafin, Learning Technologies and Xero.

We are also of the view that the share price falls of many of our longs was further exacerbated by the vacuum of newsflow during the month. October in the UK is always light on company specific news given there is no formal Q3 reporting season, therefore we believe this quiet period only served to heighten uncertainty over the outlook for many corporates.

It’s worth noting that where companies have reported, we have been on the right side for the majority, with trading patterns continuing to support our investment thesis, however share price falls not corresponding to the updates. YouGov for example reported a 10% upgrade however the shares fell more than 15% during the month. So despite the underperformance, this is a not a period where we can point to several shares that profit warned thereby compromising our investment theses, and where we have risked permanent loss of capital for our shareholders. As we believe the majority of the underperformance of our investments was driven by style and factors, as opposed to material negative company news or a change in the corporate outlook for a particular company of industry, we remain optimistic that long term value is not impaired and that the long book will recover with renewed trading updates over time.

Positive contributors to performance were predominantly companies that simply outperformed the falling market, however we did also benefit from several short positions that issued material profit warnings and therefore saw extreme share price falls, and where we have locked in some of these gains.

A lot has been written about the cause/causes of the falls during October; rising bond yields in the US, concerns around the pace of US interest rate rises, ongoing trade conflict between the US and China, and Brexit related concerns to name a few. Regardless of the initial catalyst, it is now far more important for us to determine what the implications are for global economic growth and what, if any, impact there will be on the earnings power of our investments. We still view October more as a correction than the start of a bear market or sustained GDP (Gross Domestic Product) weakness, and think there remains enough growth out there for differentiated companies to prosper. As such, overall portfolio positioning remains broadly unchanged. Given the increased level of market volatility we have deliberately reduced the portfolio’s gross and net exposure, and we have also used volatility to add to a number of our holdings where we believe that recent share price moves, do not reflect the performance of the underlying businesses. For example we have added to our holdings in Aveva, Craneware and Dechra Pharmaceuticals.

1Source: BlackRock as at 31 October 2018

29 November 2018

ENDS

Latest information is available by typing www.blackrock.co.uk/thrg on the internet, "BLRKINDEX" on Reuters, "BLRK" on Bloomberg or "8800" on Topic 3 (ICV terminal). Neither the contents of the Manager’s website nor the contents of any website accessible from hyperlinks on the Manager’s website (or any other website) is incorporated into, or forms part of, this announcement.

Date   Source Headline
27th Jun 20245:35 pmPRNTransaction in Own Shares
27th Jun 202411:34 amPRNNet Asset Value(s)
27th Jun 20247:00 amPRNTotal Voting Rights
26th Jun 20245:49 pmPRNTransaction in Own Shares
26th Jun 202411:34 amPRNNet Asset Value(s)
25th Jun 20245:58 pmPRNTransaction in Own Shares
25th Jun 202412:02 pmPRNNet Asset Value(s)
25th Jun 20247:00 amPRNTotal Voting Rights
24th Jun 202412:19 pmPRNNet Asset Value(s)
24th Jun 20248:00 amPRNPortfolio Update
21st Jun 20246:11 pmPRNTransaction in Own Shares
21st Jun 202411:35 amPRNNet Asset Value(s)
20th Jun 202411:38 amPRNNet Asset Value(s)
20th Jun 20247:00 amPRNTotal Voting Rights
19th Jun 202411:27 amPRNNet Asset Value(s)
18th Jun 20245:32 pmPRNTransaction in Own Shares
18th Jun 20241:56 pmPRNNet Asset Value(s)
18th Jun 202410:10 amPRNChange of Adviser
18th Jun 20247:00 amPRNTotal Voting Rights
17th Jun 20241:30 pmPRNMandatory Closed Period Compliance with MAR
17th Jun 202411:55 amPRNNet Asset Value(s)
14th Jun 20247:24 pmPRNTransaction in Own Shares
14th Jun 202411:40 amPRNNet Asset Value(s)
14th Jun 20247:00 amPRNTotal Voting Rights
13th Jun 202411:36 amPRNNet Asset Value(s)
13th Jun 20247:00 amPRNTotal Voting Rights
12th Jun 20246:15 pmPRNTransaction in Own Shares
12th Jun 202412:15 pmPRNNet Asset Value(s)
12th Jun 20247:00 amPRNTotal Voting Rights
11th Jun 20246:42 pmPRNTransaction in Own Shares
11th Jun 202412:11 pmPRNNet Asset Value(s)
11th Jun 20247:00 amPRNTotal Voting Rights
10th Jun 20245:56 pmPRNTransaction in Own Shares
10th Jun 202411:41 amPRNNet Asset Value(s)
10th Jun 20247:00 amPRNTotal Voting Rights
7th Jun 20246:00 pmPRNTransaction in Own Shares
7th Jun 202411:50 amPRNNet Asset Value(s)
7th Jun 20247:00 amPRNTotal Voting Rights
6th Jun 20245:48 pmPRNTransaction in Own Shares
6th Jun 202411:49 amPRNNet Asset Value(s)
6th Jun 20247:00 amPRNTotal Voting Rights
5th Jun 20245:46 pmPRNTransaction in Own Shares
5th Jun 20241:26 pmPRNDirector Declaration
5th Jun 202411:38 amPRNNet Asset Value(s)
5th Jun 20247:00 amPRNTotal Voting Rights
4th Jun 20246:08 pmPRNTransaction in Own Shares
4th Jun 20241:08 pmPRNNet Asset Value(s)
4th Jun 20247:00 amPRNTotal Voting Rights
3rd Jun 20245:43 pmPRNTransaction in Own Shares
3rd Jun 202411:58 amPRNNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.